Role of Worry in Addiction: Implication of Metacognitive Beliefs and Type 2 Worry

ABSTRACT Introduction According to the self‐medication hypothesis, worriers use substances to cope with their symptoms; however, some published results have challenged this hypothesis. The aim of this study is to show if worry increases the risk of SUD when it is negatively appraised by negative met...

Full description

Saved in:
Bibliographic Details
Published in:Clinical psychology and psychotherapy Vol. 31; no. 5; pp. e3048 - n/a
Main Authors: Improvisato, Priscillia, Trouillet, Raphaël, Schuldiner, Sophie, Luquiens, Amandine, Hamonnière, Tristan, Donnadieu, Hélène, Perney, Pascal
Format: Journal Article
Language:English
Published: England John Wiley and Sons, Limited 01-09-2024
Wiley
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Introduction According to the self‐medication hypothesis, worriers use substances to cope with their symptoms; however, some published results have challenged this hypothesis. The aim of this study is to show if worry increases the risk of SUD when it is negatively appraised by negative metacognitive beliefs. Method We recruited three samples: 68 patients with a severe AUD, 27 patients dependent on eating and 42 control participants. We used the Yale Food Addiction Scale‐2, the Metacognitions Questionnaire‐65, the UPPS‐P Impulsive Behaviour Scale and the Anxiety Thoughts Inventory. Results We confirmed a direct effect of worries and metaworry on alcohol (AUD) and eating addiction (EA), but our multivariate analyses revealed that metacognitive beliefs and metaworry are the most robust predictors of alcohol and eating addiction. Discussion We reported substance‐related differences in the relationship between worry and addiction. AUD is related to the metacognitive activity set in motion by worries while EA is associated with a maladaptive form of worry (meta‐worry) where worries are negatively interpreted.
Bibliography::
Priscillia Improvisato: PhD. Student, Laboratory Epsylon (EA4556), University of Paul Valéry Montpellier 3, Montpellier; Raphaël Trouillet, PhD, Assistant Professor, Laboratory Epsylon (EA4556), University of Paul Valéry Montpellier 3, Montpellier; Sophie Schuldiner: M.D., PhD., VBIC, INSERM U1047, Univ Montpellier, Service Des Maladies Métaboliques Et Endocriniennes, CHU Nîmes, Clinique du Pied Gard Occitanie, Route de Carnon, 30240, Le Grau du Roi, France.; Amandine Luquiens: M.D., PhD, Department of Addictology, CHU Nîmes, Univ Montpellier, Nîmes, France, CESP, Univ. Paris‐Sud, UVSQ, INSERM, Université Paris‐Saclay, Villejuif, France; Tristan Hamonnière: PhD, UR Clipsyd, Université Paris Nanterre, Nanterre, France; Hélène Donnadieu: M.D., PhD., Department of Addictology, Montpellier University Hospital, Montpellier, France, Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM U1058, EFS, CHU Montpellier, Montpellier, France; Pascal Perney: M.D., PhD, Addictions Department, CHU Caremeau, Nîmes, France, Inserm U1018, Hôpital Paul Brousse, Villejuif, France.
Authors note
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1063-3995
1099-0879
1099-0879
DOI:10.1002/cpp.3048